• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering

Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced melanoma

Jul 25, 2022 | 2022, Press Releases, Scientific

More details

Philogen to attend the 3rd Annual Cytokine-Based Drug Development Summit, Boston (July 26-29, 2022)

Jun 27, 2022 | 2022, Past Events, Scientific

Philogen will attend the 3rd Annual Cytokine-Based Drug Development Summit in Boston.   Roberto De Luca, Head of Antibody Therapeutics, will give a virtual lecture entitled “Antibody-cytokine fusion proteins against Fibroblast Activation Protein (FAP)” on the 28...

Philogen receives authorisation to initiate new study in France to evaluate Nidlegy™ in several non-melanoma skin cancers

Feb 17, 2022 | 2022, Press Releases, Scientific

More details

Philogen announces publication of PET clinical data with proprietary ultra-high affinity FAP-targeting small molecule ligand (OncoFAP)

Jan 7, 2022 | 2022, Press Releases, Scientific

More info here

Philogen announces new collaboration with Janssen to discover small molecule therapeutics

Nov 24, 2021 | 2021, Press Releases, Scientific

More datails

Philogen provides Corporate Update

Nov 12, 2021 | 2021, Press Releases, Scientific

Philogen to hold a Webinar at 11 am EST / 4 pm GMT / 5 pm CET on Friday 12th November 2021, Click here to view Press Release 12-11-2021
« Older Entries
Next Entries »

Recent Posts

  • Deposito del Verbale dell’Assemblea degli Azionisti
  • Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa al Primo Trimestre 2026
  • The Board of Directors approves the financial position for the first quarter of 2026 (Courtesy English Translation)
  • Philogen to attend the 74th American Society Mass Spectrometry annual conference in San Diego, May 31 – June 4 2026
  • Philogen to attend the Society of Nuclear Medicine and Molecular Imaging (SNMM) annual meeting on May 30 – June 2, 2026

Recent Comments

    Legal

    Privacy Policy

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it